Evaluation of 3D re-cellularized tissue engineering: a drug-induced hepatotoxicity model for hepatoprotectant research

Abstract

Background: Application of hepatoprotectants, such as drugs or cytokines, can reduce drug-induced hepatotoxicity (DIH). Due to species-specific differences and abnormal cell polarity and drug-metabolizing enzymes (DMEs), in vivo animal models and in vitro 2D plastic dishes are not good DIH models. The aim of this study was to evaluate whether 3D re-cellularized liver is a sensitive, accurate and efficient DIH model for evaluation of hepatoprotectants.

Methods: 2D plastic dishes and 3D decellular liver scaffolds were perfused with HepG2 cells or augmenter of liver regeneration (ALR)-HepG2 cells. These two cell lines were exposed to 4 μM troglitazone (TRO) or 20 μM diclofenac sodium (DIC) on day 8. DME-related genes were analyzed by quantitative reverse transcription polymerase chain reaction; morphological images were revealed by immunohistochemistry, scanning electron microscopy, transmission electron microscopy, and hematoxylin and eosin staining.

Results: DME activity and cell polarity were retained and lower doses of TRO and DIC led to DIH in 3D re-cellularized liver. This DIH model reflected the protective effects and mechanism of ALR, which is one of the hepatoprotectants. ALR reduced mitochondrial damage, decreased transaminase level, and alleviated inflammation in TRO-DIH and DIC-DIH. Our re-cellularized liver lobe also showed the effect of ALR in suppressing expression of DMEs.

Conclusions: Drug-induced 3D re-cellularized tissue engineering is a sensitive, accurate, and efficient DIH model for evaluation of hepatoprotectants.

Keywords:

• 3D re-cellularized liver tissue
• augmenter of liver regeneration
• drug-induced hepatotoxicity; drug metabolic enzyme; extracellular matrix

Disclosure statement

None of the authors have any conflicting interests.

Additional information

Funding

This article was supported by National Key R&D Program of China [No. 2017YFA0103000]; Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support [No. ZYLX201806]; “Beijing Municipal Administration of Hospitals” Ascent Plan [No. DFL20151601]; National Science and Technology Key Project on “Major Infectious Diseases such as HIV/AIDS, Viral Hepatitis Prevention and Treatment” [No. 2012ZX10002004-006, 2017ZX10203201-005, 2017ZX10201201-001-001, 2017ZX10201201-002-002, 2017ZX10202203-006-001, 2017ZX10302201-004-002].